Aizempa 10 mg / 25 mg FC tablets.
PDF Leaflet Revision Date: 19 February 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Adjunct treatment for type 2 diabetes and heart failure.
Dosage (summary)
Starting dose: 10 mg once daily; may increase to 25 mg if needed.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Increased risk of hypoglycaemia with insulin/sulphonylureas
- May enhance diuretic effects
Contraindications
- Hypersensitivity to empagliflozin
- Type 1 diabetes
- Ketoacidosis
- Moderate to severe renal impairment
Common side effects
- Hypoglycaemia
- Genital infections
- Urinary tract infections
Counselling Points
- Monitor for signs of ketoacidosis
- Stay hydrated
- Report any genital or urinary symptoms
Serious warnings
- Risk of diabetic ketoacidosis
- Volume depletion
- Fournier's gangrene
On This Page
Loading package insert…
Medinsert AI
Hello! I am Medinsert Ai. What would you like to know about this professional information leaftleft?
